Novo Nordisk says its drug CargiSema cuts body weight by 22.7% in adults
Danish pharmaceutical company Novo Nordisk’s combination drug achieved a 22.7% weight-loss reduction compared to a dummy drug during end-stage trials, according to a.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Danish pharmaceutical company Novo Nordisk’s combination drug achieved a 22.7% weight-loss reduction compared to a dummy drug during end-stage trials, according to a.
The US Food and Drug Administration has approved Ionis Pharmaceuticals’ drug to treat a rare and life-threatening genetic disease known as familial chylomicronemia.
US-based Merck Inc., two late-stage studies have met the main efficacy goal of suppressing the HIV-1 virus in adults receiving different antiretroviral therapies,.
HQ Team December 19, 2024: Recent studies have revealed a significant relationship between food allergies and atopic dermatitis (AD) in pediatric patients, indicating.
Bharti Jayshankar December 19, 2024: The U.S. Food and Drug Administration (FDA) has issued a black box warning for Veozah, a medication designed.
HQ Team December 18, 2024: Taxi and ambulance drivers may have a lower risk of dying from Alzheimer’s disease compared to many other.
HQ Team December 18, 2024: Self-administered test for human papillomavirus, HPV, can help women self screen for risk of cervical cancer, according to.
HQ Team December 18, 2025: Russia recently announced the development of a cancer vaccine, which is expected to be available for distribution free.
Bharti Jayshankar December 17, 2024: The ICOD (Improving Condition in Down Syndrome) project has reported promising findings from its phase 1/2 clinical trial.
HQ Team December 17, 2024: In a study conducted in Churchill, Manitoba—often dubbed the “Polar Bear Capital of the World”—researchers from Dalhousie University.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com (opens in a new window)